[Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens].
To study the efficacy of the fluoroquinolone maxaquin (lomefloxacin), the latter was used in 27 patients with destructive bacillary pulmonary tuberculosis which progressed with routine drug regimens. After monthly therapy, positive clinical changes were achieved in 85.6% of patients, abacillation was obtained in 33.2%, a X-ray decrease in infiltrative and focal changes was recorded in 81.5% and decay cavitary closure occurred in 22.2% of patients at month 3 of maxaquin therapy. The positive clinical, laboratory, and X-ray changes occurring after the use of maxaquin necessitates the supplementation of this agent to the drug regimen for patients with progressive pulmonary tuberculosis. Mycobacterial resistance to the major drugs is an indication for the use of maxaquin.
Mar'iandyshev
A O
AO
State Medical Academy, Arkhangel'sk.
Klinberg
N M
NM
Shonbina
A I
AI
Moroz
M I
MI
D000328:Adult; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects*; D018450:Disease Progression; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D015363:Quinolones / Q000627:therapeutic use*; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy / Q000209:etiology; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*
D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D024841:Fluoroquinolones; D015363:Quinolones; C053091:lomefloxacin